Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 May;32(5):769-73.
doi: 10.2337/dc08-1872.

Diabetic subjects diagnosed through the Diabetes Prevention Trial-Type 1 (DPT-1) are often asymptomatic with normal A1C at diabetes onset

Taylor M Triolo  1 , H Peter Chase, Jennifer M Barker; DPT-1 Study Group
Affiliations

Diabetic subjects diagnosed through the Diabetes Prevention Trial-Type 1 (DPT-1) are often asymptomatic with normal A1C at diabetes onset

Taylor M Triolo et al. Diabetes Care. 2009 May.

Abstract

Objective: Upon diagnosis of type 1 diabetes, patients are usually symptomatic, and many have ketoacidosis. Screening for islet autoantibodies (IAs) has been shown to decrease A1C level and rate of hospitalization at diabetes onset. Metabolic tests and the presence of symptoms were described at diabetes onset during the Diabetes Prevention Trial-Type 1 (DPT-1).

Research design and methods: The DPT-1 screened relatives of patients with type 1 diabetes for islet cell autoantiobodies (ICAs). Those with positive ICAs had intravenous and oral glucose tolerance tests (IVGTTs and OGTTs) and were randomized into one of two prevention trials. Throughout the DPT-1 parenteral and oral insulin study, 246 people were diagnosed with type 1 diabetes.

Results: Of the 246 subjects diagnosed with diabetes, 218 had data regarding the presence of symptoms, and 138 (63.3%) reported no symptoms suggestive of diabetes. Eight subjects (3.67%) presented with ketosis. Subjects presented with a mean +/- SD A1C of 6.41 +/- 1.15%. At diagnosis, 90 subjects (50.8%) had A1C in the normal range (<6.2%). OGTT data at the time of diagnosis indicate that 35.4% had a glucose result of <100 mg/dl at 0 min.

Conclusions: The majority of subjects diagnosed with type 1 diabetes through the DPT-1 were asymptomatic at onset and had normal fasting glucose and A1C levels. This suggests that intermittent screening (IA followed by OGTT) may allow diagnosis of diabetes before severe metabolic decompensation. Screening with A1C will miss identifying many of the subjects with newly diagnosed type 1 diabetes in this cohort.

PubMed Disclaimer

Figures

Figure 1
Figure 1
A1C at onset for those diagnosed with type 1 diabetes during the DPT-1 and the last reported A1C for those randomized in DPT-1 but not diagnosed with type 1 diabetes. A: A1C for those diagnosed with type 1 diabetes (n = 177) compared with the last reported A1C for those randomized into the trial but not diagnosed with type 1 diabetes (n = 456). These groups were significantly different (P < 0.0001). B: ROC analysis of those diagnosed with type 1 diabetes compared with those randomized but not diagnosed with type 1 diabetes.
Figure 2
Figure 2
OGTT C-peptide results at 120 min for those diagnosed with type 1 diabetes during the trial (n = 175) compared with the last reported OGTT for those not diagnosed with diabetes (n = 649). For those diagnosed with diabetes, all OGTT tests were within 50 days of diagnosis (P < 0.0001).
Figure 3
Figure 3
Mean ± SE OGTT C-peptide for those diagnosed with type 1 diabetes versus those randomized in DPT-1 but not diagnosed with type 1 diabetes. Mean values are shown at 0, 30, 60, 90, and 120 min of 2-h OGTT within 50 days of diagnosis of type 1 diabetes for those diagnosed and the last reported OGTT for those randomized but not diagnosed with diabetes (P < 0.0001).
See this image and copyright information in PMC

Comment in

References

    1. Libman I, Songer T, LaPorte R: How many people in the U.S. have IDDM? Diabetes Care 1993; 16: 841– 842 - PubMed
    1. Songer TJ, LaPorte R, Lave JR, Dorman JS, Becker DJ: Health insurance and the financial impact of IDDM in families with a child with IDDM. Diabetes Care 1997; 20: 577– 584 - PubMed
    1. Wenzlau JM, Juhl K, Yu L, Moua O, Sarkar SA, Gottlieb P, Rewers M, Eisenbarth GS, Jensen J, Davidson HW, Hutton JC: The cation efflux transporter ZnT8 (Slc30A8) is a major autoantigen in human type 1 diabetes. Proc Natl Acad Sci U S A 2007; 104: 17040– 17045 - PMC - PubMed
    1. Verge CF, Gianani R, Kawasaki E, Yu L, Pietropaolo M, Jackson RA, Chase HP, Eisenbarth GS: Prediction of type I diabetes in first-degree relatives using a combination of insulin, GAD, and ICA512bdc/IA-2 autoantibodies. Diabetes 1996; 45: 926– 933 - PubMed
    1. Bingley PJ, Bonifacio E, Williams AJK, Genovese S, Bottazzo GF, Gale EAM: Prediction of IDDM in the general population: strategies based on combinations of autoantibody markers. Diabetes 1997; 46: 1701– 1710 - PubMed

Publication types

MeSH terms